Licarbazepine-D8 | CAS 1261393-17-2 - Request Quote
Licarbazepine-D8
| SZ CAT No: | SZ-E034D03 |
| CAS No | 1261393-17-2 |
| Mol.F. | C15H6D8N2O2 |
| Mol.Wt. | 262.3 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Licarbazepine-D8 is chemically 10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-2,3,4,6,7,8,11,11-d8-5-carboxamide. Licarbazepine-D8 is supplied with detailed characterization data compliant with regulatory guideline. Licarbazepine-D8 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Eslicarbazepine acetate.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 1261393-17-2
Purchase 1261393-17-2
Order 1261393-17-2
Enquire 1261393-17-2
price of 1261393-17-2
1261393-17-2 Supplier
1261393-17-2 Manufacturer
1261393-17-2 Exporter
buy high quality Licarbazepine-D8
Purchase Licarbazepine-D8
Licarbazepine-D8 suppliers
Licarbazepine-D8 manufacturers
Licarbazepine-D8 price
Order Licarbazepine-D8
Enquire Licarbazepine-D8
Licarbazepine-D8 cost
Licarbazepine-D8 Supplier
Licarbazepine-D8 Distributor
Licarbazepine-D8 for Method Validation
Eslicarbazepine acetate Reference Standard
Licarbazepine-D8 for ANDA Filing
Licarbazepine-D8 for Forced Degradation Studies
Licarbazepine-D8 Identification Standards
Licarbazepine-D8 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.